参考文献/References:
[1] 李小秋, 李甘地, 高子芬, 等. 中国淋巴瘤亚型分布:国内多中心性病例10002例分析[J]. 诊断学理论与实践, 2012, 11(2):111-115. D0I:10.3969/i.issn.1671-2870.2012.02.006. Li XQ, Li GD, Gao ZF, et al. Distribution pattern of lymphoma subtypes in China:A nation wide multicenter study of 10002 cases[J]. J Diagn Concepts Pract, 2012,11(2):111-115.
[2] Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas[J]. J Clin Oncol, 1999, 17(4):1244-1253. DOI:10.1200/JCO.1999.17.4.1244.
[3] Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma:consensus of the imaging subcommittee of international harmonization project in lymphoma[J]. J Clin Oncol, 2007, 25(5):571-578. DOI:10.1200/JCO.2006.08.2305.
[4] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5):579-586.DOI:10.1200/JCO.2006.09.2403.
[5] Meignan M, Gallamini A, Meignan M, et al. Report on the first international workshop on interim-PET-scan in lymphoma[J]. Leuk Lymphoma, 2009, 50(8):1257-1260. DOI:10.1080/10428190903040048.
[6] Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma:consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol, 2014, 32(27):3048-3058. DOI:10.1200/JCO.2013.53.5229.
[7] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma:the Lugano classification[J]. J Clin Oncol,2014, 32(27):3059-3068. DOI:10.1200/JCO.2013.54.8800.
[8] Fallanca F, Alongi P, Incerti E, et al. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL:a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC)[J]. Eur J Nucl Med Mol Imaging, 2016, 43(10):1837-1848. DOI:10.1007/s00259-016-3390-9.
[9] Nols N, Mounier N, Bouazza S, et al. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma[J].Leuk Lymphoma, 2014, 55(4):773-780. DOI:10.3109/10428194. 2013.831848.
[10] Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma:comparison between Deauville criteria and △SUVmax[J]. Eur J Nucl Med Mol Imaging, 2013, 40(9):1312-1320. DOI:10.1007/s00259-013-2435-6.
[11] Safar V, Dupuis J, Itti E, et al. Interim[18F]fluorodeoxy glucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab[J]. J Clin Oncol, 2012, 30(2):184-190. DOI:10.1200/JCO.2011. 38. 2648.
[12] Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma[J].Blood, 2011, 118(1):37-43. DOI:10.1182/blood-2010-12-327767.
[13] Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-Cell lymphoma:prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring[J]. Radiology,2016, 280(1):220-229. DOI:10.1148/radiol.2015150689.
[14] Shen G, Ma H, Pang F, et al.Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer:a meta-analysis[J/OL]. Acta Radiologica, 2017:284185117706609.[2017-05-06]. http://journals.sagepub.com/doi/pdf/10.1177/0284185117706609.[published online ahead of print May 5, 2017]. DOI:10.1177/0284185117706609.
[15] Mylam KJ, El-Galaly TC, Hutchings M, et al. Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2014, 55(7):1563-1569. DOI:10.3109/10428194. 2013.850165.
[16] 丁重阳, 李天女, 孙晋, 等. 化疗中期及终末期18F-FDG PET/CT显像对弥漫性大B细胞淋巴瘤患者预后评估价值[J]. 中华核医学与分子影像杂志, 2014, 34(6):461-465. DOI:10.3760/cma.j.issn.2095-2848.2014.06.010. Ding CY, Li TN, Sun J, et al. Prognostic value of interim and post-therapy 18F-FDG PET/CT in pafients with diffuse large b-cell lymphoma[J]. Chin J Nucl Med Mol Imaging, 2014, 34(6):461-465.
[17] 胡娜, 吴永港, 肖立志,等. 18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J]. 国际放射医学核医学杂志, 2015, 39(4):342-347. DOI:10.3760/cma.j.issn.1673-4114.2015.04.015. Hu N, Wu YG, Xiao LZ, et al. Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J]. Int J Radiat Med Nucl Med, 2015, 39(4):342-347.
[18] Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2014, 41(11):2017-2022. DOI:10.1007/s00259-014-2822-7.
[19] Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Haematol, 2014, 92(5):382-389. DOI:10.1111/ejh.12268.
[20] Xie M, Wu K, Liu Y, et al. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma:a meta-analysis with 702 participants[J]. Med Oncol, 2015, 32(1):446.DOI:10.1007/s12032-014-0446-1.
[21] Ceriani L, Martelli M, Conconi A, et al. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18F-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study[J]. Br J Haematol, 2017, 178(4):588-591. DOI:10.1111/bjh.14728.
[22] International Non-Hodgkin’s Lymphoma Prognostic Factors Project.A predictive model for aggressive non-Hodgkin’s lymphoma[J]. N Engl J Med, 1993, 329(14):987-994. DOI:10.1056/NEJM1993099303291402.
[23] Sehn Lh, Berry B, Chhanabhai M, et al. The revised International Prognostic Index(R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. Blood, 2007, 109(5):1857-1861. DOI:10.1182/blood-2006-08-038257.
[24] Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014, 123(6):837-842. DOI:10.1182/blood-2013-09-524108.
[25] 宋腾, 王华庆, 张会来, 等. 改良国际预后指数(NCCN-IPI)对R-CHOP方案治疗弥漫大B细胞淋巴瘤的预后评估(附168例临床分析)[J].中国肿瘤临床, 2015, 42(21):1050-1055. DOI:10.3969/j.issn.1000-8179.2015.21.977. Song T, Wang HQ, Zhang HL, et al. Prognostic significance of an enhanced International Prognostic Index(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated with R-CHOP:a case report of 168 patients[J]. Chin J Clin Oncol, 2015, 42(21):1050-1055.
[26] Melchardt T, Troppan K, Weiss L, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2-microglobulin[J]. Br J Haematol, 2015, 168(2):239-245. DOI:10.1111/bjh.13116.
[27] Altan M, Haberal HB, Akdogan B, et al. A critical prognostic analysis of neutrophil-lymphocyte ratio for patients undergoing nephroureterectomy due to upper urinary tract urothelial carcinoma[J]. Int J Clin Oncol, 2017, 22(5):964-971. DOI:10.1007/s10147-017-1150-x.
[28] Huang Y, Feng JF, Liu JS, et al. Prognostic role of serum C-reactive protein in esophageal cancer:a systematic review and meta-analysis[J]. Ther Clin Risk Manag, 2015, 11:89-94. DOI:10.2147/TCRM.S70954.
[29] Panizo C, Rodríguez AJ, Gutiérrez G, et al. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy:results of the PRO-R-IPI study[J]. Clin Lymphoma Myeloma Leuk, 2015, 15(7):398-403. DOI:10. 1016/j.clml.2015.02.029.
[30] Wang J, Zhou X, Liu Y, et al.Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma:A meta-analysis[J/OL]. PLoS One, 2017, 12(4):e0176008[2017-05-01].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404792/pdf/pone.0176008.pdf.DOI:10.1371/journal.pone.0176008.
[31] Herishanu Y, Perry C, Braunstein R, et al. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin’s lymphoma[J]. Eur J Haematol, 2007, 79(2):150-154.DOI:10.1111/j.1600-0609.2007.00894.x.
[32] Troppan KT, Schlick K, Deutsch A, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients[J]. Br J Cancer, 2014, 111(1):55-60. DOI:10.1038/bjc.2014.277.
[33] Wang J, Zhou M, Wang X, et al. Pretreatment C-reactive protein was an Independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP[J]. Clin Chim Acta, 2016, 459(459):150-154. DOI:10.1016/j.cca.2016.05.033.
[34] Kanemasa Y, Shimoyama T, Sasaki Y, et al. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients[J]. Med Oncol,2017, 34(2):29. DOI:10.1007/s12032-017-0885-6.
[35] Kawamoto K, Miyoshi H, Yoshida N, et al. MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma[J]. Cancer Sci, 2016, 107(6):853-861. DOI:10.1111/cas.12942.
[36] Petrella T, Copie-Bergman C, Brière J, et al. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial[J]. Ann Oncol, 2017, 28(5):1042-1049. DOI:10.1093/annonc/mdx022.
[37] Bari A, Marcheselli L, Marcheselli R, et al. Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients[J]. Br J Haematol, 2016. DOI:10.1111/bjh.14406.
[38] Kong Y, Qu L, Li Y, et al. Predictive significance of a new prognostic score for patients with diffuse large B-Cell lymphoma in the Interim-Positron emission tomography findings[J/OL]. Medicine(Baltimore),2016, 95(6):e2808[2017-03-01]. http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4753946&blobtype=pdf. DOI:10. 1097/MD.0000000000002808.
[39] Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma:systematic review and meta-analysis[J]. Br J Haematol, 2015, 170(2):185-191. DOI:10.1111/bjh.13420.
相似文献/References:
[1]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[2]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[3]胡娜,吴永港,肖立志,等.18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J].国际放射医学核医学杂志,2015,39(4):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
Hu Na,Wu Yonggang,Xiao Lizhi,et al.Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):342.[doi:10.3760/cma.j.issn.1673-4114.2015.04.015]
[4]戴娜,吴翼伟.影像学技术在霍奇金淋巴瘤诊疗中的价值[J].国际放射医学核医学杂志,2014,38(2):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
Dai Na,Wu Yiwei.The value of medical imaging methods in diagnosis and treatment of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):117.[doi:10.3760/cma.j.issn.1673-4114.2014.02.011]
[5]杨希,党春江.泌尿系统原发性结外淋巴瘤的临床及影像学表现[J].国际放射医学核医学杂志,2013,37(4):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
YANG Xi,DANG Chun-jiang.The clinical and imaging appearances of primary extranodal lymphoma of the urinary system[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):230.[doi:10.3760/cma.j.issn.1673-4114.2013.04.010]
[6]李艳梅,杨建伟,李鹏,等.单眼虹膜原发非霍奇金淋巴瘤18F-FDGPET/CT显像及疗效评价一例[J].国际放射医学核医学杂志,2013,37(5):326.[doi:10.3760/cma.j.issn.1673-4114.2013.05.017]
[7]王月英,吴红英,李德冠,等.小鼠不同肿瘤模型对放化疗敏感性的研究[J].国际放射医学核医学杂志,2012,36(5):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
WANG Yue-ying,WU Hong-ying,LI De-guan,et al.The radiation sensitivities of different mice tumor model to radiotherapy and chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):289.[doi:10.3760/cnla.j.issn.1673-4114.2012.05.006]
[8]李倩,刘建军.18F-FDG PET-CT评价淋巴瘤疗效及预后的价值[J].国际放射医学核医学杂志,2011,35(4):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
LI Qian,LIU Jian-jun.The value of 18F-FDG PET-CT in lymphoma therapy evaluation and prognosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):220.[doi:10.3760/cma.j.issn.1673-4114.2011.04.006]
[9]崔玥婵,朱晓琳,张雪君.超声引导下穿刺活检术对颈部淋巴结诊断的现状及进展[J].国际放射医学核医学杂志,2011,35(6):369.[doi:10.3760,cma.j.issn.1673-4114.2011.06.013]
CUI Yue-chaan,ZHU Xiao-lin,ZHANG Xue-jun.Status and advances of cervical lymph nodes diagnosis by ultrasound-guided core-needle biopsy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):369.[doi:10.3760,cma.j.issn.1673-4114.2011.06.013]
[10]袁航,章斌,邓胜明,等.淋巴瘤细胞株Raji摄取18F-氟脱氧葡萄糖和18F-氟脱氧胸腺嘧啶核苷的体外实验研究[J].国际放射医学核医学杂志,2009,33(6):327.[doi:10.3760/cma.j.issn.1673-4114.2009.06.002]
YUAN Hang,ZHANG Bin,DENG Sheng-ming,et al.In vitro study of uptaking 18F-fluorodeoxyglucose and 18-fluorodeoxythymidine in human lymphoma Raji cell[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):327.[doi:10.3760/cma.j.issn.1673-4114.2009.06.002]
[11]萨日,赵红光,关锋,等.18F-FDG PET/CT在弥漫性大B细胞淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2013,37(1):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
SA Ri,ZHAO Hong-guang,GUAN Feng,et al.Clinical value of 18F-FDG PET/CT in evaluation of curative effect on diffuse large B cell lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(6):9.[doi:10.3760/cma.j.issn.1673-4114.2013.01.003]
[12]魏莉,罗荣城.放射性核素标记抗CD20单克隆抗体治疗B细胞淋巴瘤的研究进展[J].国际放射医学核医学杂志,2006,30(3):153.
WEI Li,LUO Rong-cheng.Advances in research of radioactive nuclide labeled anti-CD20 monoclonal antibody in B cell lymphomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):153.